Whom and How to Treat: Weighing the Costs and Effects

Scandinavian Journal of Gastroenterology, Supplement

Volumn 38, Issue 239, 2003, Pages 3-10

  Van Hout, B A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cost effectiveness; Health care; Health economics

Indexed keywords

PROTON PUMP INHIBITOR;

CANCER PATIENT; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DYSPEPSIA; EDUCATION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INTENSIVE CARE UNIT; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; VACCINATION; COST BENEFIT ANALYSIS; HEALTH CARE ORGANIZATION; REVIEW; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH CARE RATIONING; HUMANS; TREATMENT OUTCOME;

EID: 1642497618     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Glasser JH, Chrzanowski RS. Medical technology assessment, appropriate methods, valuable answers. Health Policy 1988;3:267-76.
2. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 2nd edn. Oxford, Oxford Medical Publications;
3. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
4. Ontario Ministry of Health., Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto: Ontario Ministry of Health; 1994.
5. Commonwealth Department of Human Services and Health (Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee including major submissions involving economic analyses). Canberra: Australian Government Publishing Service; 1995.
6. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990;10:212-4.
7. Mansley EC, McKenna MT. (Importance of perspective in economic analyses of cancer screening decisions). Lancet 2001;358:1169-73.
8. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24.
9. Serruys PW, Van Hout B, Bonnier B, et al. Randomised comparison of implantation of heparin-coated stent with balloon angioplasty in selected patients with coronary artery disease (Benestent II). The Lancet 1998;352:673-81.
10. Vincent JL, Moreno R, Takala J, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Int Care Med 1996;7:707-10.
11. Zwart-van Rijkom JEF, van Hout BA. Cost-efficacy in interventional cardiology: results from the EPISTENT study. Eur Heart J 2001;22:1476-84.
12. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27.
13. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
14. Quartin AA, Schein RM, Kett DH, et al. Magnitude and duration of the effect of sepsis on survival. JAMA 1997;277:1058-63.
15. Koopmanschap MA, Rutten FFH, Van Ineveld BM, Van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89.
16. Fayers PM, Machn D. Quality of life, assessment, analysis and interpretation. Chichester: John Wiley; 2000.
17. Bowling A. Measuring disease: a review of life measurement scales. Philadelphia: Open University Press; 1995.
18. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
19. Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu ZL, DePauw S, Denton M, Boyle M. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care, 2002;40:113-28.
20. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
21. Van Hout BA, Al M, Gordon GS, Rutten FFH. Costs, effects and C/E-ratio's alongside a clinical trial. Health Econ 1994;3:309-19.
22. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40.
23. Van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors: Who to treat? Eur Heart J 2001;22:751-61.